SciSparc Subsidiary NeuroThera Labs Closes Majority Acquisition of CliniQuantum
TipRanks (Thu, 4-Jun 8:39 AM ET)
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
Globe Newswire (Thu, 4-Jun 7:32 AM ET)
Market Chameleon (Thu, 28-May 5:52 AM ET)
Market Chameleon (Thu, 28-May 5:03 AM ET)
Globe Newswire (Thu, 28-May 8:40 AM ET)
Globe Newswire (Mon, 16-Mar 8:20 AM ET)
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
Globe Newswire (Fri, 13-Mar 7:45 AM ET)
Globe Newswire (Thu, 12-Mar 7:55 AM ET)
Globe Newswire (Tue, 10-Mar 9:28 AM ET)
Clearmind’s MEAI-PEA Patent Targets $226 Billion Obesity and Liver Disease Market
Market Chameleon (Tue, 10-Mar 5:15 AM ET)
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Scisparc Ltd. - trades on the NASDAQ stock market under the symbol SPRC.
As of June 5, 2026, SPRC stock price declined to $11.44 with 137,632 million shares trading.
SPRC has a beta of 2.71, meaning it tends to be more sensitive to market movements. SPRC has a correlation of 0.03 to the broad based SPY ETF.
SPRC has a market cap of $6.47 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, SPRC traded as high as $3,243.70 and as low as $2.98.
SPRC has underperformed the market in the last year with a return of -81.0%, while SPY returned +25.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SPRC shares. However, SPRC has outperformed the market in the last 3 month and 2 week periods, returning +105.8% and +167.9%, while SPY returned +8.5% and -1.1%, respectively. This indicates SPRC has been having a stronger performance recently.
SPRC support price is $10.13 and resistance is $12.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRC shares will trade within this expected range on the day.
